Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Bioengineering for Building Microphysiological Systems 2022

Daniel Levner's Biography



Daniel Levner, Chief Technology Officer, Emulate, Inc.

Daniel Levner, PhD, is Chief Technology Officer at Emulate, Inc. A serial deep-tech entrepreneur, Dr. Levner co-founded Emulate and brings to it extensive experience in biological and engineering technology development and commercialization. Dr. Levner joined Emulate's founding team during his role as a Senior Staff Scientist at the Wyss Institute for Biologically Inspired Engineering at Harvard University. There, he led the advanced engineering team responsible for developing the Emulate Organs-on-Chips platform and played a key leadership role formulating innovative approaches for bridging biologists, engineers, and business stakeholders.

Prior to directing the Organs-on-Chips program, Dr. Levner worked with world-renowned Harvard geneticist Prof. George M. Church in programs related to medical diagnostics, DNA/RNA sequencing, and multiplexed biological sample analysis techniques. As an entrepreneur, Dr. Levner also co-founded a medical diagnostics company, and earlier in his career, an optical telecommunications startup company.

Dr. Levner received his Ph.D. in Electrical Engineering from Stanford University as well as an M.S. in Aeronautics and Astronautics, also from Stanford. He has authored numerous publications and more than 70 issued and pending patents.

Daniel Levner Image

Organ-Chips: New Applications, Predictive Validity and Economic Implications

Monday, 24 October 2022 at 17:30

Add to Calendar ▼2022-10-24 17:30:002022-10-24 18:30:00Europe/LondonOrgan-Chips: New Applications, Predictive Validity and Economic ImplicationsBioengineering for Building Microphysiological Systems 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Organ-on-a-Chip technology continues to evolve both in the breadth of the applications that it addresses, as well as in the depth of its qualification data and understanding of its contexts of use.  In this presentation, we review recent work on modeling immune-cell recruitment for applications in the study of inflammation and immune-oncology.  In addition, we discuss the qualification of the Emulate Liver-Chip using a framework defined by the Innovation and Quality (IQ) consortium, as well as an evaluation of its predictive value against known clinical outcomes using a blinded set of 27 hepatotoxic and non-toxic drugs.  We conclude by exploring the potential financial impact that could result from the adoption of the Emulate Liver-Chip in the small-molecule pharmaceutical industry and estimate that the level of accuracy displayed in this study could generate $3 billion annually due to increased R&D productivity.


Add to Calendar ▼2022-10-24 00:00:002022-10-25 00:00:00Europe/LondonBioengineering for Building Microphysiological Systems 2022Bioengineering for Building Microphysiological Systems 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com